Literature DB >> 15314263

Drug discovery: estrogen-related compounds in mouse models of Alzheimer's disease.

Jonathan D Smith1, Enakshi Chakrabarti, Justine A Levin-Allerhand.   

Abstract

Despite promising epidemiological studies that showed a decreased incidence of Alzheimer disease (AD) in women who used hormone replacement therapy (HRT), the results of the recently released Women's Health Initiative Memory Study has dampened any enthusiasm for the use of HRT in women to prevent or delay the onset of AD. In this position paper, we review these data, along with our own--using estrogens in a transgenic mouse model of AD--and introduce our current working hypothesis and research. Copyright 2004 Humana Press Inc.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15314263     DOI： 10.1385/JMN:24:1:145

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


  8 in total

1.  Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis.

Authors:  Jeffrey P Greenfield; Lawrence W Leung; Dongming Cai; Krista Kaasik; Rachel S Gross; Enrique Rodriguez-Boulan; Paul Greengard; Huaxi Xu
Journal:  J Biol Chem       Date:  2002-01-31       Impact factor: 5.157

2.  Effect of estradiol on neuronal Swedish-mutated beta-amyloid precursor protein metabolism: reversal by astrocytic cells.

Authors:  B Vincent; J D Smith
Journal:  Biochem Biophys Res Commun       Date:  2000-04-29       Impact factor: 3.575

3.  Neuroprotection against oxidative stress by estrogens: structure-activity relationship.

Authors:  C Behl; T Skutella; F Lezoualc'h; A Post; M Widmann; C J Newton; F Holsboer
Journal:  Mol Pharmacol       Date:  1997-04       Impact factor: 4.436

4.  Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides.

Authors:  H Xu; G K Gouras; J P Greenfield; B Vincent; J Naslund; L Mazzarelli; G Fried; J N Jovanovic; M Seeger; N R Relkin; F Liao; F Checler; J D Buxbaum; B T Chait; G Thinakaran; S S Sisodia; R Wang; P Greengard; S Gandy
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

5.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

Authors:  M X Tang; D Jacobs; Y Stern; K Marder; P Schofield; B Gurland; H Andrews; R Mayeux
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

6.  The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia.

Authors:  S A Shumaker; B A Reboussin; M A Espeland; S R Rapp; W L McBee; M Dailey; D Bowen; T Terrell; B N Jones
Journal:  Control Clin Trials       Date:  1998-12

7.  17Alpha-estradiol and 17beta-estradiol treatments are effective in lowering cerebral amyloid-beta levels in AbetaPPSWE transgenic mice.

Authors:  Justine A Levin-Allerhand; Chris E Lominska; Jennifer Wang; Jonathan D Smith
Journal:  J Alzheimers Dis       Date:  2002-12       Impact factor: 4.472

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272
  8 in total
  1 in total

Review 1.  Intriguing roles of hippocampus-synthesized 17β-estradiol in the modulation of hippocampal synaptic plasticity.

Authors:  Chen Bian; Haitao Zhu; Yangang Zhao; Wenqin Cai; Jiqiang Zhang
Journal:  J Mol Neurosci       Date:  2014-04-15       Impact factor: 3.444
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.